🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseSemaglutide liver fat quantification — MRI-PDFF data from multiple trials

Semaglutide liver fat quantification — MRI-PDFF data from multiple trials

MASHdoc_SA Tue, Jun 2, 2026 at 9:22 AM 22 replies 672 viewsPage 1 of 5
MASHdoc_SA
Member
456
2,345
Aug 2024
San Antonio, TX
Jun 2, 2026 at 9:22 AM#1

Putting this up for argument rather than for agreement. I have read it twice and I am still not certain what it supports.

The dose-response is real but shallow at the top. Across STEP 1 and STEP 4 the gap between 1.7mg and 2.4mg is a couple of percentage points of body weight on average, and the average is carrying a wide spread — plenty of people at 1.7mg sit above the 2.4mg mean. If a dose is working and tolerable, "working" is the relevant variable, not "maximal".

Where I think it is weakest: the subgroup findings are the part I trust least — with enough subgroups something is always significant, and these were not all pre-registered.

So the question, as narrowly as I can put it: whether anyone has held at a sub-maximal dose long term and kept the result, or whether the maintenance data only exists at 2.4mg. If the honest answer is that nobody knows, that is a useful answer and I would rather have it.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
13 8TirzTom, TrialTracker_MD, JennaRN and 10 others
Reply Quote Save Share Report
Dr.GutHealth
Senior Member
1,456
7,890
Mar 2024
Minnesota
Jun 2, 2026 at 9:31 AM#2
MASHdoc_SA said:
The dose-response is real but shallow at the top.

All true, with one condition: that curve is for people who reached the dose on schedule. Anyone who slowed the ladder for tolerability is on a different, flatter curve, and comparing yourself with the published mean will make you feel like a non-responder when you are not.

12 7tyler_CSCS, VanRx_Mike, steve_okc and 9 others
Reply Quote Save Share Report
DebRD_ATL
Senior Member
1,678
7,890
Feb 2024
Atlanta, GA
Jun 2, 2026 at 9:40 AM#3
MASHdoc_SA said:
The dose-response is real but shallow at the top.

I will push back on the "any working dose is fine" framing. The maintenance evidence sits overwhelmingly at the top studied dose, and the extension data shows regain tracking dose reduction rather than tracking stopping. Holding low is reasonable; pretending it is evidentially equivalent is not.

I would rather be corrected than agreed with, if it comes to it.

Last edited: Jun 2, 2026 at 1:40 PM
11 6SleepDoc_PDX, RegAffairsDC, BiostatsBrad and 8 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
paige_pharma
Member
289
1,234
Sep 2024
Omaha, NE
Jun 2, 2026 at 9:49 AM#4

Answering the narrow version, because the broad one does not have a single answer. Steady state is the thing most people miss. The terminal half-life is about a week, so every dose step takes four to five weeks to fully express itself. Judging a step at day ten is judging the ascent, not the plateau, and it is the single commonest reason people escalate before they needed to.

Ask again with the specifics and you will get a better answer than this one.

Last edited: Jun 2, 2026 at 10:49 AM
10 5lisa_labSD, adam_van, Dr.SurgeonPGH and 7 others
Reply Quote Save Share Report
mark_tokyo
Member
456
1,890
Jun 2024
Tokyo, JP
Jun 2, 2026 at 10:37 AM#5
Dr.GutHealth said:
All true, with one condition: that curve is for people who reached the dose on schedule.

That holds for the injectable. The oral formulation has different absorption behaviour and the dose numbers are not interchangeable, which is worth saying out loud because people quote them as if they were.

9 4TrialNerd_Beth, HPLC_Greg, LibrarianMeg and 6 others
Reply Quote Save Share Report
1235

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register